Letermovir Recruiting Phase 3 Trials for CMV Disease Prevention

IndicationsStatusPurposePhase
RecruitingPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT03443869Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)